{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:08Z","timestamp":1791571748673,"version":"4.3.4"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>We investigate safety and efficacy in common clinical practice of the combination of carfilzomib and dexamethasone (Kd56) approved for the ENDEAVOR trial for the treatment of relapsed or refractory multiple myeloma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retro\u2010prospective analyzed 75 patients in three centers in Tuscany, 48 of whom had a clinically relevant comorbidity and 50 of whom were older than 65\u2009years, treated with a median use in the fourth line of therapy. We assessed the efficacy based on the International Myeloma Working Group criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall response rate was 60%. Median PFS was 10\u00a0months in the general cohort; in patients treated for more than 1\u00a0cycle of therapy PFS was 12\u2009months. Quality of response to Kd56 treatment was found to positively impact PFS. Refractory status to previous line of therapy or to lenalidomide or an history of exposure to pomalidomide, seemed to have no impact on survival. We also showed a low adverse events rate, with no neuropathy events, and a relatively small number of cardiovascular events above grade 3 (10%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Kd56 is an effective and well tolerated regimen in highly pretreated and elderly patients with a good safety profile.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13819","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T15:19:01Z","timestamp":1656083941000},"page":"373-380","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro\u2010prospective observational study"],"prefix":"10.1111","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4291-8875","authenticated-orcid":false,"given":"Maria Livia","family":"Del Giudice","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Hematology University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gozzetti","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Ospedaliera Universitaria Senese University of Siena  Siena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Antonioli","sequence":"additional","affiliation":[{"name":"Hematology, Careggi Hospital University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Attucci","sequence":"additional","affiliation":[{"name":"Hematology, Careggi Hospital University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Pengue","sequence":"additional","affiliation":[{"name":"Hematology, Careggi Hospital University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Cassano Cassano","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Hematology University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ghio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Hematology University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Orciuolo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Hematology University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Simoncelli","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Ospedaliera Universitaria Senese University of Siena  Siena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Ospedaliera Universitaria Senese University of Siena  Siena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Hematology University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5240-5611","authenticated-orcid":false,"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Hematology University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"e_1_2_10_3_1","unstructured":"Myeloma: Surveillance Epidemiology and End Results Program: SEER Stats Facts Sheet\u2014Myeloma. Accessed February 13 2022.https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201010\u2010116129"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201004\u2010403733"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-6-508"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9707-8"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120030218"},{"key":"e_1_2_10_10_1","first-page":"4996","article-title":"Proteasome inhibitor PS\u2010341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc R","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201013\u20100755"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858415"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(20)30756\u20107"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201001\u2010631200"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001059"},{"key":"e_1_2_10_21_1","unstructured":"ClinicalTrials.gov.Identifier NCT03091127 Real\u2010world Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy 19. Accessed February 13 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03091127"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30734\u20100"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201099\u2010112600"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.703233"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.643490"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14780"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.129189"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13819","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13819","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T09:17:49Z","timestamp":1692436669000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/ejh.13819"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13819","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"2022-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}